Ongoing Clinical Trials

at Tata Medical Center

We are on a mission of bringing hope to life. You can join us and make this journey, yours.

Droplet Droplet Clinical Hematology
PreviousNext
Multiple Myeloma Trials Indication Recruitment Ongoing Contact Details (Email ID) Contact Number
Teclistamab Phase 4 Myeloma progressing after Daratumumab Yes tanushree.dutta.c@tmckolkata.net 033-6605-7832
DreaMM10 Newly Diagnosed Multiple Myeloma : Belantamab-VRD Vs Daratumumab VRD Yes nilanjana.bharati.c@tmckolkata.net 033-6605-7622
Iberdomide Maintenance therapy After Autologous Stem Cell Transplantation Yes nitya.infoclin@gmail.com 033-6605-7622
LeukeamiaTrials Indication Recruitment Ongoing Contact Details (Email ID) Contact Number
Renew Study Erythropoietin refractory / intolerant Myelodysplastic syndrome Will start recruitment soon sutapa.chatterjee.c@tmckolkata.com 033-6605-7622
Lymphoma Trials Indication Recruitment Ongoing Contact Details (Email ID) Contact Number
ADITI Lymphoma refractory to all conventional treatments Yes sutapa.chatterjee.c@tmckolkata.com 033-6605-7622
Brentuximab Phase III Newly Diagnosed Hodgkin Lymphoma : generic vs innovator Will Start Soon anindita.bandyopadhyay.c@tmckolkata.com 033-6605-7832
Transplant Trials Indication Recruitment Ongoing Contact Details (Email ID) Contact Number
Latermovir Prevention of CMV reactivation and infection post allogeneic stem cell transplant Yes srija.biswas.c@tmckolkata.net 033-6605-7832
Rezurock (Belumosudil) Steroid refractory chronic GVHD post 2 lines treatment Will start soon avijit.gole.c@tmckolkata.net 033-6605-7832
SAFE-FMT Ruxolitinib and FMT combinmation in steroid refractory Gut GVHD Yes jashasreenayak75@gmail.com 033-6605-7832
Iberdomide Maintenance therapy After Autologous Stem Cell Transplantation Yes nitya.infoclin@gmail.com 033-6605-7622